GLP-1 Feud: HIMS Fires Back At Novo Nordisk, Slams Lawsuit As "Blatant Attack" By Big Pharma
Novo Nordisk is suing HIMS for selling unapproved copies of Wegovy, prompting HIMS to call it a "blatant attack" by Big Pharma.Summary
Novo Nordisk has filed a lawsuit against HIMS & Hers Health, alleging the telehealth company unlawfully markets unapproved versions of its semaglutide medicines, Wegovy and Ozempic, endangering patients and infringing on patents. HIMS responded by characterizing the lawsuit as a “blatant attack by a Danish company on millions of Americans” who rely on compounded medications, accusing Big Pharma of using the legal system to limit consumer choice. The dispute began after HIMS launched a copycat GLP-1 pill for $49 a month, significantly cheaper than Novo Nordisk’s $149 Wegovy pill, leading to a 20% drop in HIMS’s stock price and a 7% increase in Novo Nordisk’s shares. The FDA also warned against the mass marketing of these unapproved drugs, raising concerns about their quality, safety, and effectiveness, and HIMS subsequently halted sales of its copycat pill. Novo Nordisk seeks a permanent ban on HIMS selling unapproved drugs and recovery of damages.
(Source：Zerohedge)